Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]
Received 1 March 2019
Accepted for publication 1 March 2019
Published 24 July 2019 Volume 2019:14 Pages 5751—5752
Wu H, Infante JR, Keedy VL, et al. Int J Nanomedicine. 2015:10;1201—1209
On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]